Loading clinical trials...

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE3

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

NCT06683742•EyePoint Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit.
•Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1).
•For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.

Exclusion Criteria

•Subfoveal fibrosis, atrophy, or scarring in the center subfield.
•BCVA using ETDRS charts \<20 letters (20/400 Snellen equivalent) in the fellow eye.

Locations (140)

Associated Retina Consultans

Gilbert, Arizona, United States

Associated Retina Consultants - Phoenix

Phoenix, Arizona, United States

Phoenix Retina Clinical Trials, LLC

Phoenix, Arizona, United States

Retina Macula Institute of Arizona

Scottsdale, Arizona, United States

Win Retina

Arcadia, California, United States

Doctor Retina, PC

Beverly Hills, California, United States

The Retina Partners

Encino, California, United States

RCOC Clinical Research Institute Inc.

Fullerton, California, United States

Global Research Management, Inc.

Glendale, California, United States

Atlantis Eyecare

Huntington Beach, California, United States

Key Dates

Start Date

November 27, 2024

Primary Completion Date

October 1, 2026

Completion Date

October 1, 2027

Last Updated

March 3, 2026

Enrollment

400

ESTIMATED participants

Conditions

Wet Age Related Macular DegenerationwAMD

Interventions

EYP-1901

DRUG

Aflibercept (2.0 mg)

DRUG

Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD

NCT06718816

View study

COMPLETED

CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking

NCT07255885

MaculopathyMaculopathy, Age Related+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Inclusion Criteria

Exclusion Criteria

Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD

CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking

Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

Optical Coherence Tomography Angiography Criteria Of The Choroidal Neovascular Membrane In Wet Age Related Macular Degeneration And In Pathological Myopia (Comparative Study).